The new lawsuit argues that the board’s action conflicted with federal patent laws by not allowing the company to charge as ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to ...

Polypharmacy in RA patients is linked to increased drug interaction risks, especially with immunosuppressants, necessitating careful management and monitoring. Older age and multiple comorbidities are ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

The study showed that with each increasing year of age, the odds of receiving contraceptive counseling decreased by 5%.